Clinical trials: Epilepsy
Epilepsy, Partial-onset Seizures
A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures
This study is to evaluate the long-term safety and tolerability of Lacosamide (LCM) 200 mg/day to LCM 600 mg/day taken in monotherapy in Japanese subjects who currently have partial-onset seizures with or without secondary…
- Trial name
- NCT02124564
- Testing
- Lacosamide
- Where
- 11 sites in Japan
- Volunteers
- 19 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy
Steps for Epilepsy
The purpose of this research study is to evaluate the feasibility of a 12-week, telehealth delivered, step-goal based physical activity intervention in people with epilepsy.
- Trial name
- StEpi (NCT05359003)
- Testing
- 12-week Physical Activity Program
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Lennox Gastaut Syndrome
A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with…
- Trial name
- NCT03355209
- Testing
- ZX008 0.2 or 0.8 mg/kg/day
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 296 people
- Sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Mitochondrial Diseases
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study…
- Trial name
- NCT02473445
- Testing
- Cysteamine Bitartrate
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
- Trial name
- NCT04873869
- Testing
- NBI-921352
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Neurocrine Biosciences
Epilepsy
Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures
The purpose of this Phase III study is to evaluate the efficacy, safety and tolerability and health outcomes of retigabine Immediate Release (IR) as adjunctive therapy to each of the following monotherapy Antiepileptic Drug (AED)…
- Trial name
- IR (NCT01227902)
- Testing
- Retigabine IR
- Where
- 66 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 203 people
- Sponsor
- GlaxoSmithKline
Convulsion, Non-Epileptic
Auricular Acupuncture For The Treatment Of Non-Epileptic Seizures
This feasibility study will determine the tolerability of auricular acupuncture, compliance with self-reported seizure tracking, and the quality of a proposed sham acupuncture protocol to inform the design of a large…
- Trial name
- NCT01919307
- Testing
- Auricular acupuncture
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Denver Health and Hospital Authority
Epilepsies, Partial
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
This study will determine the safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy subjects for the treatment of partial seizures.
- Trial name
- NCT00524030
- Testing
- pregabalin 600 mg/day, pregabalin 150 mg/day
- Where
- 73 sites in United States, Czechia and 2 more
- Volunteers
- 161 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy
The purpose of this study is to evaluate the long-term retention rate of topiramate in participants with epilepsy (seizure disorder).
- Trial name
- NCT01682681
- Testing
- Topiramate
- Volunteers
- 1,234 people
- Sponsor
- Janssen Korea, Ltd., Korea
Epilepsy
Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers
To investigate the pharmacokinetics of a single 900 mg oral dose of BIA 2-093 and a single 900 mg oral dose of Oxcarbazepine in healthy volunteers and to assess the tolerability of a single 900 mg dose of BIA 2-093 and…
- Trial name
- NCT01678976
- Testing
- BIA 2-093, Oxcarbazepine
- Where
- Portugal
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Nonconvulsive Status Epilepticus, Subclinical Seizure
EEG Cap for Identification of Non-Convulsive Status Epilepticus
Altered mental status (AMS) is one of the most common reasons for inpatient neurology consultation. Non-convulsive status epilepticus (NCSE) is frequently on the differential diagnosis of the patient with AMS.
- Conditions
- Nonconvulsive Status Epilepticus, Subclinical Seizure, Altered Mental Status, Nonepileptic Seizures
- Trial name
- NCT03138876
- Testing
- EEG Cap, Anti-seizure medication, Standard EEG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Elderly, Epilepsy
Tolerability and Efficacy of Depakote-extended Release in the Elderly
There is a bimodal distribution to the new onset seizures with one peak occurring in the very young and the second peak occurring in persons over age 65 years.
- Conditions
- Elderly, Epilepsy, Seizures
- Trial name
- NCT00318929
- Testing
- Divalproex Sodium Extended-Release Tablets
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Virginia Commonwealth University
Renal Impairment
A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment
The primary objectives of this study are to evaluate the pharmacokinetics (PK) following administration of gabapentin in Japanese epileptic patients with renal impairment to confirm if there are any clinically relevant…
- Trial name
- NCT00785772
- Testing
- Gabapentin
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Seizure, Epilepsy
A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM
Pediatric cerebral malaria (CM) affects more than 3 million children each year killing ~20% and leaving one third of survivors with long term neurologic and psychiatric sequelae.
- Conditions
- Seizure, Epilepsy, Cerebral Malaria
- Trial name
- LVT2 (NCT01982812)
- Testing
- Oral Levetiracetam, Standard AED
- Where
- Malawi
- Volunteers
- 44 people
- Sponsor
- University of Rochester
Seizures
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
This is a multicenter, open-label trial to assess the long-term safety and efficacy of Cannabidiol Oral Solution as adjunctive therapy for pediatric participants with treatment-resistant seizure disorders, including…
- Trial name
- NCT02318602
- Testing
- Cannabidiol Oral Solution
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- INSYS Therapeutics Inc
Refractory Partial Onset Seizures
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301.
- Trial name
- NCT00448539
- Testing
- Rufinamide
- Where
- 27 sites in United States
- Volunteers
- 286 people
- Sponsor
- Eisai Inc.
Partial Epilepsy
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
This purpose of this study is to measure the concentrations of two anti-epileptic drugs (Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid and blood plasma of healthy subjects and also to…
- Trial name
- NCT00900237
- Testing
- Eslicarbazepine acetate, Oxcarbazepine
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Inherited Mitochondrial Disease, Including Leigh Syndrome
Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease
To evaluate safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) administered at a target maintenance dose of 1.3 g/m²/day in two divided doses, every 12 hours, for up to 6 months in…
- Trial name
- MITO-001 (NCT02023866)
- Testing
- Cysteamine Bitartrate
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Amgen
Partial Epilepsies, Partial Onset Seizures
Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures
The purpose of the trial is to evaluate the safety of intravenous (iv) lacosamide delivered in a single dose followed by 6.5 days of oral lacosamide treatment in subjects with partial-onset seizures.
- Trial name
- NCT00655551
- Testing
- lacosamide
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy
fMRI Guided TMS Enhancement of Associative Memory Networks
This is a randomized, single-blinded, controlled phase 1 study to demonstrate feasibility and explore the neurophysiologic and clinical effects of repetitive transcranial magnetic stimulation (TMS) interventions in epilepsy…
- Trial name
- NCT02749422
- Testing
- MagStim RapidStim2
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health